Sinovac Biotech Ltd. Stock Upgraded (SVA)

NEW YORK ( TheStreet) -- Sinovac Biotech (Nasdaq: SVA) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Highlights from the ratings report include:
  • SVA's very impressive revenue growth greatly exceeded the industry average of 3.1%. Since the same quarter one year prior, revenues leaped by 131.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • SVA's debt-to-equity ratio is very low at 0.17 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 3.00, which clearly demonstrates the ability to cover short-term cash needs.
  • The gross profit margin for SINOVAC BIOTECH LTD is rather high; currently it is at 66.00%. It has increased significantly from the same period last year. Despite the strong results of the gross profit margin, SVA's net profit margin of 13.10% significantly trails the industry average.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market on the basis of return on equity, SINOVAC BIOTECH LTD has outperformed in comparison with the industry average, but has underperformed when compared to that of the S&P 500.
  • SVA's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 53.41%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
.

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against the hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Sinovac Biotech has a market cap of $120.8 million and is part of the health care sector and drugs industry. Shares are down 6.4% year to date as of the close of trading on Friday.

You can view the full Sinovac Biotech Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null

If you liked this article you might like

3 Biotech Stocks Under $10 in Breakout Territory

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China

Sinovac Biotech Ltd. Stock Downgraded (SVA)

Sinovac Biotech Ltd. Stock Upgraded (SVA)

Rev Shark: An Odd Market Day